Mayur is finishing his Ph.D in Biomedical Engineering at Columbia University where he cofounded Ardent Cell Technologies, a cell therapeutics company entering clinical trials. Before joining Columbia he worked at Boston Consulting Group designing predictive models and precision medicine product pipelines for healthcare giants like Boston Scientific. He believes that opportunities shaping and contributing towards value based care are the way forward.
When a startup is four or five people, they pretty much have no leverage unless it?s an exceptional startup with a lot of traction in the market which rarely happens in the history of time. Usually there is not much leverage in a startup.Again, I?ll go back to the last point. You go back to findin...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
